Page 7 - Sciences Ltd News Today

Roivant Sciences Ltd is attracting interest from large pharmaceutical companies for its inflammatory bowel disease drug, Bloomberg News reported on Thursday, citing people familiar with the matter. ...

SPC Life Sciences has received approval from the Securities and Exchange Board of India (Sebi) to raise funds through an initial public offering (IPO). The IPO will consist of fresh equity shares worth Rs 300 crore and an Offer For Sale of 89.39 lakh equity shares by the companys promoter. The company may also consider a pre-IPO placement of up to Rs 60 crore. Proceeds from the IPO will be used to pay debt, support working capital needs, fund capital expenditure, and expand product offerings.

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Rating) major shareholder Global Investors Lp Viking sold 13,000,000 shares of the stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $9.90, for a total value of $128,700,000.00. Following the transaction, the insider now directly owns 641,010 shares of […]

Cantor Fitzgerald restated their overweight rating on shares of Roivant Sciences (NASDAQ:ROIV – Get Rating) in a research report sent to investors on Tuesday morning, PriceTargets.com reports. A number of other equities analysts also recently weighed in on ROIV. JPMorgan Chase & Co. boosted their price target on shares of Roivant Sciences from $12.00 to […]

Roivant Sciences (NASDAQ:ROIV – Get Rating) and 23andMe (NASDAQ:ME – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership. Institutional and Insider Ownership 60.6% of Roivant Sciences shares are owned […]

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Rating) COO Eric Venker sold 299,384 shares of the firm’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $9.91, for a total transaction of $2,966,895.44. Following the sale, the chief operating officer now owns 660,097 shares of the […]

Bank of America initiated coverage on shares of Roivant Sciences (NASDAQ:ROIV – Get Rating) in a research note published on Thursday, The Fly reports. The brokerage issued a neutral rating and a $10.50 price target on the stock. Several other equities research analysts have also recently weighed in on ROIV. HC Wainwright upped their price […]

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Rating) COO Eric Venker sold 299,384 shares of the stock in a transaction on Friday, June 9th. The stock was sold at an average price of $9.91, for a total transaction of $2,966,895.44. Following the sale, the chief operating officer now directly owns 660,097 shares of the company’s stock, […]

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Rating) COO Eric Venker sold 299,384 shares of Roivant Sciences stock in a transaction on Friday, June 9th. The stock was sold at an average price of $9.91, for a total transaction of $2,966,895.44. Following the sale, the chief operating officer now directly owns 660,097 shares of the company’s […]

Investment analysts at Bank of America initiated coverage on shares of Roivant Sciences (NASDAQ:ROIV – Get Rating) in a research report issued on Thursday, The Fly reports. The brokerage set a “neutral” rating and a $10.50 price target on the stock. Bank of America‘s target price points to a potential upside of 4.69% from the […]